Expert Q&A: Labs Must Take a Greater Role in Guiding Clinicians About Abnormal Data
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Lab Industry Advisor
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Subscribe today for access to
Articles and Reports
FDA Watch: Could Guardant Health’s Colon Cancer Assay Be a Blockbuster?
The company is hiring at least 100 sales representatives this year to spread awareness and uptake of its recently FDA-approved Shield test
At-Home Genetic Testing: The Good, The Bad, and The Ugly
Direct-to-consumer (DTC) genetic testing has risen in popularity in recent years—but is it all it’s cracked up to be?
Inside the Lab Industry: COVID-19 Declines Kill Top Lab Company Earnings but Genetic Firms Rebound
Yet, despite these declines, Q1 was neither as bad as expected nor totally devoid of positive signs for the future.
Three Strategies for Creating a Sustainable Recruiting Model
What should pathology groups and labs do in order to attract and maintain clinical talent in today’s economy?
M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
June 2023 FDA Watch
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
DX Deals: Large Healthcare Bankruptcies Rebound from Pandemic Lull
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
Compliance Tool: Model Mandatory Excluded Provider Screening Policy
A written policy helps establish your right to do excluded persons checks and take appropriate actions if they come back positive.
Labs in Court
In recent key cases, the national drug retailer must stand trial for failing to protect customers from faulty Theranos products.
Billing & Coding: What to Know About New Category III CPT Codes for Digital Pathology
The new codes have garnered attention as a future mechanism for additional reimbursement and thus deserve further discussion.
Compliance Perspectives: How to Perform Excluded Provider Checks
Hiring, retaining, or simply doing business with the wrong people may expose your lab to significant financial penalties.
Kentucky $1.74 Million Settlement Illustrates the Danger of Billing Medicare for Nonmedical Urine Drug Tests
A recent False Claims Act settlement from Kentucky represents an unusual variation on a common theme.
